Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19)

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031138

Enrollment

Unknown

Registered

2020-03-22

Start date

2020-02-26

Completion date

Unknown

Last updated

2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe COVID-19

Interventions

Pirfenidone group:Support treatment with oral taken Pirfenidone capsule

Support treatment group:Support treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients aged 18-80 years; (2) Clear diagnosis of patients with severe COVID-19; (3) Voluntarily join the trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Those who are allergic to pirfenidone; (2) The investigator judges that the subject's compliance is poor. (3) Patients with severe liver disease; (4) pregnant and lactating patients; (5) Those who have severe kidney disease or need dialysis treatment; (6) Those who need to take fluvoxamine at the same time

Design outcomes

Primary

Measure	Time frame
HRCT score;	—

Secondary

Measure	Time frame
Lung function;Oxygenation index;	—

Countries

China

Contacts

Public ContactMeng Jie

The Third Xiangya Hospital of Central South University

mengjie@csu.edu.cn+86 13607492399

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026